Mineralys Therapeutics Past Earnings Performance
Past criteria checks 0/6
Mineralys Therapeutics's earnings have been declining at an average annual rate of -57.5%, while the Biotechs industry saw earnings growing at 11.7% annually.
Key information
-57.5%
Earnings growth rate
0.1%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | -37.7% |
Net Margin | n/a |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Mineralys Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 0 | -91 | 16 | 89 |
31 Dec 23 | 0 | -72 | 14 | 70 |
30 Sep 23 | 0 | -57 | 12 | 54 |
30 Jun 23 | 0 | -40 | 10 | 38 |
31 Mar 23 | 0 | -35 | 7 | 32 |
31 Dec 22 | 0 | -30 | 5 | 26 |
30 Sep 22 | 0 | -28 | 4 | 25 |
31 Dec 21 | 0 | -19 | 2 | 16 |
Quality Earnings: MLYS is currently unprofitable.
Growing Profit Margin: MLYS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MLYS is unprofitable, and losses have increased over the past 5 years at a rate of 57.5% per year.
Accelerating Growth: Unable to compare MLYS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MLYS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.9%).
Return on Equity
High ROE: MLYS has a negative Return on Equity (-37.65%), as it is currently unprofitable.